Clinical Trials /

A Study of Rucaparib and Nivolumab in People With Leiomyosarcoma

NCT04624178

Description:

The purpose of this study is to find out whether combining the study drugs rucaparib and nivolumab may be an effective treatment for advanced and/or metastatic LMS, and whether the study treatment works as well as the standard chemotherapy for this type of cancer.

Related Conditions:
  • Leiomyosarcoma
Recruiting Status:

Recruiting

Phase:

Phase 2

Trial Eligibility

Document

Title

  • Brief Title: A Study of Rucaparib and Nivolumab in People With Leiomyosarcoma
  • Official Title: Phase II Study of Rucaparib and Nivolumab in Patients With Leiomyosarcoma

Clinical Trial IDs

  • ORG STUDY ID: 20-358
  • NCT ID: NCT04624178

Conditions

  • Leiomyosarcoma

Interventions

DrugSynonymsArms
RucaparibRucaparib in combination with Nivolumab
NivolumabRucaparib in combination with Nivolumab

Purpose

The purpose of this study is to find out whether combining the study drugs rucaparib and nivolumab may be an effective treatment for advanced and/or metastatic LMS, and whether the study treatment works as well as the standard chemotherapy for this type of cancer.

Trial Arms

NameTypeDescriptionInterventions
Rucaparib in combination with NivolumabExperimentalOne treatment cycle will consist of 28 days. Patients will receive rucaparib at 600 mg, orally, twice daily, continuously for 28 days. They will receive 480mg of nivolumab intravenously on day 1 of every four-week cycle. This is the recommended phase II dose of the combination therapy. Re-staging scans will be performed every 8 weeks. Treatment will be repeated until the patient develops progressive disease or unacceptable toxicity or for a maximum duration of 26 cycles as long as patients are receiving benefit from treatment, have not had disease progression, met any criteria for study withdrawal and are tolerating therapy.
  • Rucaparib
  • Nivolumab

Eligibility Criteria

        Inclusion Criteria:

          -  Male or female age ≥ 18 years at the time of informed consent

          -  Be willing and able to provide written informed consent/assent for the trial

          -  Be willing to comply with treatment protocol

          -  Subjects must have a histologically confirmed unresectable/metastatic LMS

          -  Availability of archival tissue for correlative studies. Either a paraffin block or at
             least 20 unstained slides are acceptable

          -  Adequate performance status: ECOG 0 - 2

          -  Subjects must have had at least 1 but not more than 3 prior lines of systemic therapy
             (e.g. chemotherapy, immunotherapy, targeted or biological therapy) for their LMS.
             Patients who decline the standard of care first-line systemic therapy will be eligible
             for this trial. Prior adjuvant therapy will not count provided it was completed more
             than 6 months previously.

          -  Presence of measurable disease per RECIST v1.1. Target lesions must not be chosen from
             a previously irradiated field unless there has been radiographically and/or
             pathologically documented tumor progression in that lesion prior to enrollment.

          -  Adequate organ function determined within 14 days of treatment initiation, defined as
             per Hematological

          -  Absolute neutrophil count (ANC) ≥1.5 K/mcL

          -  Platelets ≥100 K/ mcL

          -  Hemoglobin ≥9 g/dL Renal

          -  Serum creatinine OR Measured or calculated creatinine clearance Estimated glomerular
             filtration rate (eGFR) ≥ 30 mL/min/1.73 m2. For calculated CrCL, the Cockcroft Gault
             formula or institutional standard formula can be used.

        Hepatic

          -  Serum total bilirubin <1.5 X ULN OR <2 X ULN if hyperbilirubinemia is due to Gilbert's
             syndrome

          -  AST (SGOT) and ALT (SGPT) Aspartate aminotransferase (AST) and alanine
             aminotransferase (ALT) ≤ 3 × upper limit of normal (ULN); if liver metastases, then ≤
             5 × ULN Coagulation

          -  International Normalized Ratio ≤1.5 X ULN (≤ 2.5 × ULN if on anticoagulants)

          -  Women of childbearing potential must have a negative serum pregnancy test at screening
             and ≤ 72 hours prior to the first dose of study treatment.

          -  Female subjects of childbearing potential must be willing to use an adequate method of
             contraception as outlined in Section 15.1.6 and not breastfeed, for the duration of
             the study and for at least 6 months after the last after the last dose of study
             medication.

        Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception
        for the subject.

          -  Non-sterile male subjects and their female partners must be willing to use a highly
             effective method of contraception during the study treatment period and for at least 7
             months after the last dose of study treatment. Nonsterile males must avoid sperm
             donation for the duration of the study and for at least 7 months after last study
             drug.

          -  Patients who were treated with chemotherapy or any investigational therapies or other
             anti-cancer agent, if eligible, must have been completed at least 3 weeks or at least
             5 half-lives (whichever is longer, but no less than 3 weeks) before the study drug
             administration. All AEs must be ≤ NCI CTCAE v5 Grade 1, except alopecia and stable
             neuropathy, which must have resolved to Grade ≤ 2 or baseline. Patients who were
             treated with estrogen modulating therapies (aromatase inhibitors, tamoxifen, GnRH
             agonists etc.) must have been treated at least 2 weeks prior to study drug
             administration.

          -  Patients who were treated with radiotherapy must have completed radiation therapy at
             least 2 weeks before the study drug administration.

          -  Must be willing to agree to an on-treatment biopsy if deemed safe and feasible by the
             treating physician

        Exclusion Criteria:

          -  Uncontrolled intercurrent illness including current active or chronic infection
             requiring systemic therapy or the following cardiac criteria:

               -  Symptomatic congestive heart failure (NYHA classification III or IV) within 6
                  months

               -  Acute myocardial infarction ≤6 months prior to Day 1

               -  Grade ≥2 ventricular arrhythmia ≤6 months prior to Day 1

               -  History of cerebrovascular accident within 6 months before first dose of study
                  drugs

          -  Has known active central nervous system (CNS) metastases and/or carcinomatous
             meningitis. Patients with previously treated brain metastases may participate provided
             they are stable (without evidence of progression by imaging for at least four weeks
             prior to the first dose of trial treatment and any neurologic symptoms have returned
             to baseline), have no evidence of new or enlarging brain metastases, and are not using
             steroids for at least 7 days prior to trial treatment. This exception does not include
             carcinomatous meningitis which is excluded regardless of clinical stability.

          -  Evidence of clinically significant immunosuppression such as the following:

               -  Primary immunodeficiency state such as Severe Combined Immunodeficiency Disease

               -  Concurrent opportunistic infection

               -  Receiving systemic immunosuppressive therapy (> 2 weeks) including oral steroid
                  doses > 10 mg/day of prednisone or equivalent within 7 days prior to enrollment.
                  However, in the setting of non-immune mediated indications for steroid use,
                  chronic/active low dose steroid use may be permitted at the discretion of the
                  principal investigator. The dose of steroid allowed in this setting is also at
                  the discretion of the principal investigator. (Use of inhaled or topical steroids
                  is permitted.)

          -  History or evidence of symptomatic autoimmune disease (e.g., pneumonitis,
             glomerulonephritis, vasculitis, or other), or history of active autoimmune disease
             that has required systemic treatment (i.e., use of corticosteroids, immunosuppressive
             drugs or biological agents used for treatment of autoimmune diseases) in past 2 years
             prior to enrollment. Replacement therapy (e.g., thyroxine for hypothyroidism, insulin
             for diabetes or physiologic corticosteroid replacement therapy for adrenal or
             pituitary insufficiency) is not considered a form of systemic treatment for autoimmune
             disease.

          -  Known history of a positive test for human immunodeficiency virus (HIV) or known
             acquired immunodeficiency syndrome (AIDS). Has known active Hepatitis B (e.g., HBsAg
             reactive) or Hepatitis C (e.g., HCV RNA [qualitative] is detected).

          -  History of non-viral hepatitis or cirrhosis

          -  A history of alcohol abuse

          -  Use of any live vaccines (e.g., against infectious diseases such as varicella) within
             4 weeks (28 days) of initiation of study therapy

          -  Has a known history of active TB (Bacillus Tuberculosis)

          -  Prior therapy with a PARP inhibitor and/or PD-1/PD-L1 monoclonal antibody is not
             permitted.

               -  Patients who have not recovered from clinically significant adverse events of
                  prior therapy to ≤ NCI CTCAE v5 Grade 1, except alopecia and stable neuropathy,
                  which must have resolved to Grade ≤ 2 or baseline. Except for AEs not considered
                  a likely safety risk (e.g., alopecia, neuropathy)

               -  Note: If subject received major surgery, they must have recovered adequately from
                  the toxicity and/or complications from the intervention prior to starting therapy
                  events due to a previously administered agent.

          -  Presence of a gastrointestinal condition that may affect drug absorption

          -  Known allergy or reaction to any component of either study drug formulation

          -  Has evidence of active, non-infectious pneumonitis.

          -  Women who are pregnant or breast feeding

          -  Subjects expecting to have a child within the projected duration of the trial,
             starting with the pre-screening or screening visit through 6 months after the last
             dose of study treatment(s) for women or 7 months for men.

          -  Presence of any other concurrent malignancy requiring active therapy or thought to
             potentially interfere with the safe conduct or assessment of outcomes on this trial

          -  Prior allogeneic stem cell transplantation or organ transplantation.
      
Maximum Eligible Age:N/A
Minimum Eligible Age:18 Years
Eligible Gender:All
Healthy Volunteers:No

Primary Outcome Measures

Measure:Best objective response rate
Time Frame:by 24 weeks
Safety Issue:
Description:as assessed by RECIST 1.1

Secondary Outcome Measures

Measure:Progression free survival (PFS)
Time Frame:at 24 weeks
Safety Issue:
Description:PFS is defined as the period from start of study treatment until recurrent or progressive of disease (POD) is objectively documented (taking as reference for progressive disease the smallest measurement recorded on study), death, or date of last study visit involving assessment of disease status.

Details

Phase:Phase 2
Primary Purpose:Interventional
Overall Status:Recruiting
Lead Sponsor:Memorial Sloan Kettering Cancer Center

Trial Keywords

  • Rucaparib
  • Nivolumab
  • 20-358

Last Updated

November 12, 2020